Contact this trialFirst, we need to learn more about you.
MDM2 Inhibitor
KRT-232 + TKI for Chronic Myeloid Leukemia
Recruiting1 awardPhase 1 & 2
Milwaukee, Wisconsin
This trial is looking at a new drug, KRT-232, to see if it is effective in treating patients with a certain type of leukemia who have not responded well to other treatments.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service